Sclerodermiform basal cell carcinoma
Last Updated: 2023-07-07
Author(s): Anzengruber F., Navarini A.
Keloid basal cell carcinoma, fibrosing basal cell carcinoma, morpheaant basal cell carcinoma, morpheiform basal cell carcinoma, sclerosing basal cell carcinoma.
Clinically "scarring" aspect, with a more pronounced therapeutic approach usually recommended.
- Atrophic, slightly raised, scarred, partly keloid, rarely ulcerating, yellowish, waxy or ivory-coloured, indistinctly demarcated, dermal plaque with telangiectasia. One sees an increased tendency to infiltrate deep structures.
Particularly the nose, forehead or cheeks.
A connective tissue, fibromatous reaction surrounds the tumour cell clusters. Unlike other forms of BCC, the typical palisading is mostly absent.
- ↑ Risk of recurrence
- Clark CM, Furniss M, Mackay-Wiggan JM. Basal cell carcinoma: an evidence-based treatment update. Am J Clin Dermatol 2014;15:197-216.
- Kwasniak LA, Garcia-Zuazaga J. Basal cell carcinoma: evidence-based medicine and review of treatment modalities. Int J Dermatol 2011;50:645-58.
- Hauschild, A. (2016). Langfassung der Leitlinie "Basalzellkarzinom der Haut". Awmf.org. Retrieved 30 May 2016, from http://www.awmf.org/leitlinien/detail/ll/032-021.html